Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JORGE M VENEREO

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1144299009
CMS profile
324488
Location
DORAL, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$83.58

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $83.58 5

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Pharmaceuticals, Inc $65.62 4
Boehringer Ingelheim Pharmaceuticals, Inc. $17.96 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JORGE M VENEREO

NPI 1144299009 · CMS profile ID 324488

Allopathic & Osteopathic Physicians / Internal Medicine

DORAL, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144299009?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JORGE M VENEREO, NPI 1144299009, CMS profile ID 324488. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144299009?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). JORGE M VENEREO, NPI 1144299009, CMS profile ID 324488. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144299009?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
JORGE M VENEREO, NPI 1144299009, CMS profile ID 324488, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1144299009?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $83.58 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $18.2412/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719222149 CMS
Janssen Pharmaceuticals, Inc $16.2111/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719222147 CMS
Janssen Pharmaceuticals, Inc $15.4109/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719222143 CMS
Janssen Pharmaceuticals, Inc $15.7607/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719222145 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $17.9601/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720787097 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $34.17 2
PY2020 $83.58 5
PY2021 $95.63 5
PY2022 $125.00 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $978,346.35 79
PY2024 Principal investigator $750,186.73 535
PY2023 Recipient $250.00 1
PY2023 Principal investigator $1,161,263.89 753
PY2022 Recipient $450.00 1
PY2022 Principal investigator $433,849.06 425
PY2021 Recipient $437.46 1
PY2021 Principal investigator $229,625.48 182
PY2020 Principal investigator $282,764.54 64
PY2019 Principal investigator $543,958.67 209

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

754 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111135
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111143
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111271
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111277
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111283
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111289
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111295
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111301
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111307
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111315
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111321
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111327
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111333
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111339
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111345
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111351
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111357
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111363
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111369
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111375
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111381
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111387
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111393
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111399
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111405
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111411
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111417
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111423
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111430
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111435
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111441
Principal investigator 1 Alnylam Pharmaceuticals Inc. $68.00 12/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112795
Principal investigator 1 Alnylam Pharmaceuticals Inc. $146.00 12/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112801
Principal investigator 1 Alnylam Pharmaceuticals Inc. $195.00 12/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112807
Principal investigator 1 Alnylam Pharmaceuticals Inc. $390.00 12/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112813
Principal investigator 1 Alnylam Pharmaceuticals Inc. $544.00 12/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112821
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,314.00 12/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112827
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,560.00 12/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112833
Principal investigator 1 Alnylam Pharmaceuticals Inc. $64.00 12/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112839
Principal investigator 1 Alnylam Pharmaceuticals Inc. $369.00 12/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112845
Principal investigator 1 Alnylam Pharmaceuticals Inc. $61.00 12/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112919
Principal investigator 1 Alnylam Pharmaceuticals Inc. $174.00 12/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112925
Principal investigator 1 Alnylam Pharmaceuticals Inc. $218.00 12/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112931
Principal investigator 1 Alnylam Pharmaceuticals Inc. $238.00 12/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112937
Principal investigator 1 Alnylam Pharmaceuticals Inc. $505.00 12/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112943
Principal investigator 1 Alnylam Pharmaceuticals Inc. $837.00 12/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112949
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,141.00 12/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112955
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 12/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112961
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,928.00 12/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112967
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 12/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112987
Principal investigator 1 Alnylam Pharmaceuticals Inc. $138.00 12/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112993
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,436.00 12/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112999
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66.00 12/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997113011
Principal investigator 1 Alnylam Pharmaceuticals Inc. $68.00 12/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997113103
Principal investigator 1 Alnylam Pharmaceuticals Inc. $68.00 12/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997113109
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 12/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997113165
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 12/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997113171
Principal investigator 1 Janssen Research & Development, LLC $3,076.00 12/13/2023 Non-covered Recipient Entity
Pharmax Rsrch Clnc
67953964MDD3003 No dispute reported 06/30/2026 986108763
Principal investigator 1 Janssen Research & Development, LLC $13,846.00 12/08/2023 Non-covered Recipient Entity
Pharmax Rsrch Clnc
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 986108743
Principal investigator 1 Alnylam Pharmaceuticals Inc. $362.00 12/01/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997113117
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,243.00 12/01/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997113123
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,243.00 12/01/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997113129
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,243.00 12/01/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997113135
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,243.00 12/01/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997113141
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 12/01/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997113147
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 12/01/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997113153
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 12/01/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997113159
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110593
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110599
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110781
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110787
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110795
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110801
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110807
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110811
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110817
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110825
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110831
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111149
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111155
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111161
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111167
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111173
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111179
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111185
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111191
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111197
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111203
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111209
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111215
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111223
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111227
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111235
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111241
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111247
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111253
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111259
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 11/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111265
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 11/27/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112901
Principal investigator 1 Alnylam Pharmaceuticals Inc. $153.00 11/27/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112907
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,661.00 11/27/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112913
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 11/27/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997113017
Principal investigator 1 Alnylam Pharmaceuticals Inc. $153.00 11/27/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997113023
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 11/27/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997113029
Principal investigator 1 Alnylam Pharmaceuticals Inc. $153.00 11/27/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997113035
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 11/27/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997113041
Principal investigator 1 Alnylam Pharmaceuticals Inc. $153.00 11/27/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997113047
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 11/27/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997113055
Principal investigator 1 Alnylam Pharmaceuticals Inc. $153.00 11/27/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997113061
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,153.00 11/27/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997113067
Principal investigator 1 Alnylam Pharmaceuticals Inc. $153.00 11/27/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997113073
Principal investigator 1 Alnylam Pharmaceuticals Inc. $46.90 11/27/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997113079
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,661.00 11/27/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997113085
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,661.00 11/27/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997113091
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,661.00 11/27/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997113097
Principal investigator 1 Alnylam Pharmaceuticals Inc. $585.00 11/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112333
Principal investigator 1 Alnylam Pharmaceuticals Inc. $340.00 11/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112339
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,170.00 11/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112345
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,020.00 11/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112353
Principal investigator 1 Alnylam Pharmaceuticals Inc. $219.00 11/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112359
Principal investigator 1 Alnylam Pharmaceuticals Inc. $975.00 11/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112365
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,752.00 11/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112371
Principal investigator 1 Alnylam Pharmaceuticals Inc. $128.00 11/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112389
Principal investigator 1 Alnylam Pharmaceuticals Inc. $738.00 11/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112395
Principal investigator 1 Alnylam Pharmaceuticals Inc. $122.00 11/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112511
Principal investigator 1 Alnylam Pharmaceuticals Inc. $136.00 11/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112519
Principal investigator 1 Alnylam Pharmaceuticals Inc. $364.00 11/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112851
Principal investigator 1 Alnylam Pharmaceuticals Inc. $707.00 11/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112857
Principal investigator 1 Alnylam Pharmaceuticals Inc. $714.00 11/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112863
Principal investigator 1 Alnylam Pharmaceuticals Inc. $261.00 11/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112869
Principal investigator 1 Alnylam Pharmaceuticals Inc. $280.00 11/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112875
Principal investigator 1 Alnylam Pharmaceuticals Inc. $203.00 11/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112881
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,304.00 11/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112887
Principal investigator 1 Alnylam Pharmaceuticals Inc. $327.00 11/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112893
Principal investigator 1 Alnylam Pharmaceuticals Inc. $110.00 11/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112973
Principal investigator 1 Alnylam Pharmaceuticals Inc. $207.00 11/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112981
Principal investigator 1 Alnylam Pharmaceuticals Inc. $132.00 11/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997113005
Principal investigator 1 Janssen Research & Development, LLC $864.00 11/17/2023 Non-covered Recipient Entity
Pharmax Rsrch Clnc
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 986108751
Principal investigator 1 Janssen Research & Development, LLC $1,907.00 11/17/2023 Non-covered Recipient Entity
Pharmax Rsrch Clnc
67953964MDD3003 No dispute reported 06/30/2026 986108759
Principal investigator 1 Janssen Research & Development, LLC $16,964.00 11/10/2023 Non-covered Recipient Entity
Pharmax Rsrch Clnc
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 986108747
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,243.00 11/03/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112487
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,266.00 11/03/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112493
Principal investigator 1 Alnylam Pharmaceuticals Inc. $978.00 11/03/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112499
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,775.10 11/03/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112505
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,243.00 11/03/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112567
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,266.00 11/03/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112573
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,243.00 11/03/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112579
Principal investigator 1 Alnylam Pharmaceuticals Inc. $978.00 11/03/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112585
Principal investigator 1 Alnylam Pharmaceuticals Inc. $978.00 11/03/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112591
Principal investigator 1 Alnylam Pharmaceuticals Inc. $978.00 11/03/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112599
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,243.00 11/03/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112605
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 11/03/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112611
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,243.00 11/03/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112617
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 11/03/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112623
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,243.00 11/03/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112629
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,243.00 11/03/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112635
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,243.00 11/03/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112641
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,243.00 11/03/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112647
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,243.00 11/03/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112653
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,243.00 11/03/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112661
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,243.00 11/03/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112667
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,243.00 11/03/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112673
Principal investigator 1 Alnylam Pharmaceuticals Inc. $508.80 11/01/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112463
Principal investigator 1 Alnylam Pharmaceuticals Inc. $153.00 11/01/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112469
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,661.00 11/01/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112475
Principal investigator 1 Alnylam Pharmaceuticals Inc. $793.00 11/01/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112481
Principal investigator 1 Alnylam Pharmaceuticals Inc. $153.00 11/01/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112549
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,661.00 11/01/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112555
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,661.00 11/01/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112561
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110581
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110587
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110605
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110611
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110617
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110623
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110629
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110635
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110641
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110645
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110653
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110659
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110665
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110671
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110677
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110683
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110689
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110695
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110701
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110707
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110713
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110719
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110727
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110733
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110739
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110745
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110751
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110757
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110763
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110769
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 10/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110775
Principal investigator 1 Alnylam Pharmaceuticals Inc. $748.00 10/23/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112265
Principal investigator 1 Alnylam Pharmaceuticals Inc. $390.00 10/23/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112271
Principal investigator 1 Alnylam Pharmaceuticals Inc. $272.00 10/23/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112277
Principal investigator 1 Alnylam Pharmaceuticals Inc. $195.00 10/23/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112283
Principal investigator 1 Alnylam Pharmaceuticals Inc. $340.00 10/23/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112289
Principal investigator 1 Alnylam Pharmaceuticals Inc. $128.00 10/23/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112377
Principal investigator 1 Alnylam Pharmaceuticals Inc. $738.00 10/23/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112383
Principal investigator 1 Alnylam Pharmaceuticals Inc. $61.00 10/23/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112407
Principal investigator 1 Alnylam Pharmaceuticals Inc. $136.00 10/23/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112413
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 10/23/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112525
Principal investigator 1 Alnylam Pharmaceuticals Inc. $132.00 10/23/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112543
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,170.00 10/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112297
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,460.00 10/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112303
Principal investigator 1 Alnylam Pharmaceuticals Inc. $511.00 10/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112309
Principal investigator 1 Alnylam Pharmaceuticals Inc. $609.00 10/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112419
Principal investigator 1 Alnylam Pharmaceuticals Inc. $763.00 10/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112425
Principal investigator 1 Alnylam Pharmaceuticals Inc. $483.00 10/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112531
Principal investigator 1 Janssen Research & Development, LLC $29,470.00 10/13/2023 Non-covered Recipient Entity
Pharmax Rsrch Clnc
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 986108755
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66,875.00 10/04/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112401
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,340.00 10/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112315
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,263.00 10/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112321
Principal investigator 1 Alnylam Pharmaceuticals Inc. $365.00 10/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112327
Principal investigator 1 Alnylam Pharmaceuticals Inc. $476.00 10/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112433
Principal investigator 1 Alnylam Pharmaceuticals Inc. $435.00 10/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112439
Principal investigator 1 Alnylam Pharmaceuticals Inc. $406.00 10/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112445
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 10/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112451
Principal investigator 1 Alnylam Pharmaceuticals Inc. $545.00 10/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112457
Principal investigator 1 Alnylam Pharmaceuticals Inc. $345.00 10/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112537
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110229
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110235
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110315
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110321
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110327
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110332
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110339
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110345
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110351
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110355
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110361
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110367
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110373
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110381
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110387
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110393
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110399
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110487
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110495
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110501
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110507
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110513
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110519
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110525
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110531
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110537
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110543
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110549
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110555
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110561
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 09/29/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110569
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,350.80 09/26/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112185
Principal investigator 1 Alnylam Pharmaceuticals Inc. $62,592.30 09/25/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112247
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,755.00 09/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112173
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,156.00 09/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112179
Principal investigator 1 Janssen Research & Development, LLC $16,893.00 09/18/2023 Non-covered Recipient Entity
Pharmax Rsrch Clnc
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia and Inadequate Response to Current Antidepressant Therapy. No dispute reported 06/30/2026 986108739
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66.00 09/15/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112119
Principal investigator 1 Alnylam Pharmaceuticals Inc. $61.00 09/15/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112123
Principal investigator 1 Alnylam Pharmaceuticals Inc. $68.00 09/15/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112131
Principal investigator 1 Alnylam Pharmaceuticals Inc. $64.00 09/15/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112137
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 09/15/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112143
Principal investigator 1 Alnylam Pharmaceuticals Inc. $195.00 09/15/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112147
Principal investigator 1 Alnylam Pharmaceuticals Inc. $369.00 09/15/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112155
Principal investigator 1 Alnylam Pharmaceuticals Inc. $136.00 09/15/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112161
Principal investigator 1 Alnylam Pharmaceuticals Inc. $4,608.90 09/15/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112167
Principal investigator 1 Alnylam Pharmaceuticals Inc. $68.00 09/15/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112259
Principal investigator 1 Alnylam Pharmaceuticals Inc. $210.00 09/14/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110241
Principal investigator 1 Alnylam Pharmaceuticals Inc. $210.00 09/14/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110575
Principal investigator 1 Alnylam Pharmaceuticals Inc. $476.00 09/13/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112191
Principal investigator 1 Alnylam Pharmaceuticals Inc. $609.00 09/13/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112197
Principal investigator 1 Alnylam Pharmaceuticals Inc. $483.00 09/13/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112205
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,170.00 09/13/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112211
Principal investigator 1 Alnylam Pharmaceuticals Inc. $203.00 09/13/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112217
Principal investigator 1 Alnylam Pharmaceuticals Inc. $489.00 09/13/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112223
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,482.00 09/13/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112229
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48.00 09/13/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112235
Principal investigator 1 Alnylam Pharmaceuticals Inc. $872.00 09/13/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112241
Principal investigator 1 Alnylam Pharmaceuticals Inc. $132.00 09/06/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112063
Principal investigator 1 Alnylam Pharmaceuticals Inc. $136.00 09/06/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112069
Principal investigator 1 Alnylam Pharmaceuticals Inc. $122.00 09/06/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112075
Principal investigator 1 Alnylam Pharmaceuticals Inc. $182.00 09/06/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112081
Principal investigator 1 Alnylam Pharmaceuticals Inc. $128.00 09/06/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112087
Principal investigator 1 Alnylam Pharmaceuticals Inc. $110.00 09/06/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112093
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,755.00 09/06/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112099
Principal investigator 1 Alnylam Pharmaceuticals Inc. $738.00 09/06/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112106
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,360.00 09/06/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112113
Principal investigator 1 Alnylam Pharmaceuticals Inc. $136.00 09/06/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112253
Principal investigator 1 Alnylam Pharmaceuticals Inc. $12,194.10 09/01/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111989
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110015
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110021
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110119
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110125
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110131
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110137
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110247
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110253
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110259
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110267
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110273
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110279
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110285
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110291
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110297
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110303
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110309
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110405
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110409
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110415
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110421
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110427
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110433
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110439
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110445
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110451
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110457
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110463
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110469
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110475
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 08/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110481
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,365.00 08/18/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111977
Principal investigator 1 Alnylam Pharmaceuticals Inc. $952.00 08/18/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111983
Principal investigator 1 Alnylam Pharmaceuticals Inc. $522.00 08/07/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112013
Principal investigator 1 Alnylam Pharmaceuticals Inc. $414.00 08/07/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112019
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,730.00 08/07/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112025
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,097.00 08/07/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112031
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,869.00 08/07/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112037
Principal investigator 1 Alnylam Pharmaceuticals Inc. $654.00 08/07/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112043
Principal investigator 1 Alnylam Pharmaceuticals Inc. $37,089.00 08/04/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112007
Principal investigator 1 Alnylam Pharmaceuticals Inc. $12,930.30 08/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111909
Principal investigator 1 Alnylam Pharmaceuticals Inc. $132.00 08/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111915
Principal investigator 1 Alnylam Pharmaceuticals Inc. $204.00 08/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111921
Principal investigator 1 Alnylam Pharmaceuticals Inc. $136.00 08/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111927
Principal investigator 1 Alnylam Pharmaceuticals Inc. $122.00 08/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111933
Principal investigator 1 Alnylam Pharmaceuticals Inc. $130.00 08/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111941
Principal investigator 1 Alnylam Pharmaceuticals Inc. $364.00 08/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111947
Principal investigator 1 Alnylam Pharmaceuticals Inc. $128.00 08/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111953
Principal investigator 1 Alnylam Pharmaceuticals Inc. $110.00 08/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111959
Principal investigator 1 Alnylam Pharmaceuticals Inc. $585.00 08/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111965
Principal investigator 1 Alnylam Pharmaceuticals Inc. $738.00 08/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111971
Principal investigator 1 Alnylam Pharmaceuticals Inc. $136.00 08/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112057
Principal investigator 1 Eli Lilly and Company $66.81 08/02/2023 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) No dispute reported 06/30/2026 1038119367
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110003
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110009
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110027
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110033
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110039
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110045
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110051
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110057
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110063
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110069
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110075
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110083
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110089
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110095
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110101
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110107
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110113
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110143
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110149
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110155
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110161
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110167
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110175
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110181
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110185
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110193
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110199
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110205
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110211
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110217
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 07/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110223
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,100.00 07/21/2023 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
An Open-label Extension Trial of the Phase III Lipid-lowering Trials to Assess the Effect of Long Term Dosing of Inclisiran Given as Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C No dispute reported 06/30/2026 1017225533
Principal investigator 1 Alnylam Pharmaceuticals Inc. $10,377.00 07/17/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997112051
Principal investigator 1 Alnylam Pharmaceuticals Inc. $5,736.60 07/07/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111995
Principal investigator 1 Alnylam Pharmaceuticals Inc. $900.00 07/07/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997112001
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109617
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109623
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109629
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109659
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109665
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109671
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109677
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109683
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109689
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109695
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109701
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109837
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109843
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109849
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109855
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109861
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109867
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109873
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109879
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109885
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109891
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109897
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109903
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109909
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109915
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109921
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109927
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109933
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109941
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109947
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109953
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109959
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109965
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109971
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109979
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109985
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109991
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 06/30/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109997
Principal investigator 1 AstraZeneca UK Limited $49,146.65 06/27/2023 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 991128893
Principal investigator 1 GlaxoSmithKline, LLC. $1,127.70 06/27/2023 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO DEMONSTRA No dispute reported 06/30/2026 1006195573
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,652.00 06/26/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111541
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,315.00 06/26/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111547
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,730.00 06/26/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111553
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,796.00 06/26/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111559
Principal investigator 1 Alnylam Pharmaceuticals Inc. $256.00 06/26/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111603
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,476.00 06/26/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111609
Principal investigator 1 Alnylam Pharmaceuticals Inc. $34,655.40 06/26/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111757
Principal investigator 1 Alnylam Pharmaceuticals Inc. $272.00 06/26/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111763
Principal investigator 1 Alnylam Pharmaceuticals Inc. $183.00 06/26/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111769
Principal investigator 1 Alnylam Pharmaceuticals Inc. $364.00 06/26/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111775
Principal investigator 1 Alnylam Pharmaceuticals Inc. $714.00 06/26/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111781
Principal investigator 1 Alnylam Pharmaceuticals Inc. $783.00 06/26/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111787
Principal investigator 1 Alnylam Pharmaceuticals Inc. $981.00 06/26/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111793
Principal investigator 1 Alnylam Pharmaceuticals Inc. $220.00 06/26/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111829
Principal investigator 1 Alnylam Pharmaceuticals Inc. $621.00 06/26/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111835
Principal investigator 1 Alnylam Pharmaceuticals Inc. $264.00 06/26/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111879
Principal investigator 1 Alnylam Pharmaceuticals Inc. $260.00 06/26/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111885
Principal investigator 1 Alnylam Pharmaceuticals Inc. $272.00 06/26/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111903
Principal investigator 1 Alnylam Pharmaceuticals Inc. $12,825.90 06/21/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111751
Principal investigator 1 Alnylam Pharmaceuticals Inc. $264.00 06/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109635
Principal investigator 1 Alnylam Pharmaceuticals Inc. $132.00 06/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109641
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66.00 06/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109647
Principal investigator 1 Alnylam Pharmaceuticals Inc. $28.35 06/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109653
Principal investigator 1 Alnylam Pharmaceuticals Inc. $132.00 06/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109709
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,093.00 06/14/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111745
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,145.00 06/05/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111529
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,366.00 06/05/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111535
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,596.00 06/05/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111847
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,315.00 06/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111517
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,176.00 06/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111523
Principal investigator 1 Alnylam Pharmaceuticals Inc. $448.00 06/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111591
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,583.00 06/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111597
Principal investigator 1 Alnylam Pharmaceuticals Inc. $427.00 06/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111719
Principal investigator 1 Alnylam Pharmaceuticals Inc. $476.00 06/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111725
Principal investigator 1 Alnylam Pharmaceuticals Inc. $21,022.20 06/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111731
Principal investigator 1 Alnylam Pharmaceuticals Inc. $41,335.20 06/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111737
Principal investigator 1 Alnylam Pharmaceuticals Inc. $385.00 06/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111823
Principal investigator 1 Alnylam Pharmaceuticals Inc. $462.00 06/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111871
Principal investigator 1 Alnylam Pharmaceuticals Inc. $476.00 06/02/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111897
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109291
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109297
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109581
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109587
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109593
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109599
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109605
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109611
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109715
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109721
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109725
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109731
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109739
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109745
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109751
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109757
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109763
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109769
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109775
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109781
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109787
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109793
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109799
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109805
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109811
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109819
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109825
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 05/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109831
Principal investigator 1 Alnylam Pharmaceuticals Inc. $897.00 05/12/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111841
Principal investigator 1 Alnylam Pharmaceuticals Inc. $23,625.90 05/03/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111707
Principal investigator 1 Alnylam Pharmaceuticals Inc. $62,826.30 05/03/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111713
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109211
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109217
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109223
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109305
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109311
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109317
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109323
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109329
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109335
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109341
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109347
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109353
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109359
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109365
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109371
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109377
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109383
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109389
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109395
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109401
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109407
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109413
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109419
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109425
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109433
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109439
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109445
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109451
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109457
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109463
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109469
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109475
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109481
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109489
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109495
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109501
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109507
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109513
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109519
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109525
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109531
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109537
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109543
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109549
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109555
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109561
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109567
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 04/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109575
Principal investigator 1 Alnylam Pharmaceuticals Inc. $544.00 04/24/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111467
Principal investigator 1 Alnylam Pharmaceuticals Inc. $780.00 04/24/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111473
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,560.00 04/24/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111503
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,536.00 04/24/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111511
Principal investigator 1 Alnylam Pharmaceuticals Inc. $256.00 04/24/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111577
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,737.00 04/24/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111585
Principal investigator 1 Alnylam Pharmaceuticals Inc. $130.00 04/24/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111645
Principal investigator 1 Alnylam Pharmaceuticals Inc. $182.00 04/24/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111651
Principal investigator 1 Alnylam Pharmaceuticals Inc. $244.00 04/24/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111657
Principal investigator 1 Alnylam Pharmaceuticals Inc. $272.00 04/24/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111663
Principal investigator 1 Alnylam Pharmaceuticals Inc. $310.00 04/24/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111695
Principal investigator 1 Alnylam Pharmaceuticals Inc. $340.00 04/24/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111701
Principal investigator 1 Alnylam Pharmaceuticals Inc. $220.00 04/24/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111805
Principal investigator 1 Alnylam Pharmaceuticals Inc. $280.00 04/24/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111817
Principal investigator 1 Alnylam Pharmaceuticals Inc. $260.00 04/24/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111859
Principal investigator 1 Alnylam Pharmaceuticals Inc. $264.00 04/24/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111865
Principal investigator 1 Alnylam Pharmaceuticals Inc. $272.00 04/24/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111891
Principal investigator 1 Alnylam Pharmaceuticals Inc. $210.00 04/23/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109279
Principal investigator 1 GlaxoSmithKline, LLC. $1,492.78 04/21/2023 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 1006195583
Principal investigator 1 GlaxoSmithKline, LLC. $2,352.75 04/21/2023 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 1006195627
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,560.00 04/19/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111455
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,972.00 04/19/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111461
Principal investigator 1 Alnylam Pharmaceuticals Inc. $660.00 04/17/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109285
Principal investigator 1 Alnylam Pharmaceuticals Inc. $390.00 04/14/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111491
Principal investigator 1 Alnylam Pharmaceuticals Inc. $408.00 04/14/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111499
Principal investigator 1 Alnylam Pharmaceuticals Inc. $186.00 04/14/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111669
Principal investigator 1 Alnylam Pharmaceuticals Inc. $204.00 04/14/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111675
Principal investigator 1 Alnylam Pharmaceuticals Inc. $234.00 04/14/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111681
Principal investigator 1 Alnylam Pharmaceuticals Inc. $545.00 04/14/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111688
Principal investigator 1 Alnylam Pharmaceuticals Inc. $168.00 04/14/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111811
Principal investigator 1 Alnylam Pharmaceuticals Inc. $176.00 04/13/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109255
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66.00 04/13/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109261
Principal investigator 1 Alnylam Pharmaceuticals Inc. $462.00 04/13/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109267
Principal investigator 1 Alnylam Pharmaceuticals Inc. $528.00 04/13/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109273
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,176.00 04/12/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111479
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,340.00 04/12/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111485
Principal investigator 1 Alnylam Pharmaceuticals Inc. $176.00 04/10/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109231
Principal investigator 1 Alnylam Pharmaceuticals Inc. $396.00 04/10/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109237
Principal investigator 1 Alnylam Pharmaceuticals Inc. $66.00 04/10/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109243
Principal investigator 1 Alnylam Pharmaceuticals Inc. $594.00 04/10/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109249
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,720.00 04/07/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111129
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,120.00 04/07/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111449
Principal investigator 1 Alnylam Pharmaceuticals Inc. $320.00 04/07/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111565
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,845.00 04/07/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111571
Principal investigator 1 Alnylam Pharmaceuticals Inc. $130.00 04/07/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111615
Principal investigator 1 Alnylam Pharmaceuticals Inc. $244.00 04/07/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111621
Principal investigator 1 Alnylam Pharmaceuticals Inc. $272.00 04/07/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111627
Principal investigator 1 Alnylam Pharmaceuticals Inc. $408.00 04/07/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111633
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,313.00 04/07/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111639
Principal investigator 1 Alnylam Pharmaceuticals Inc. $220.00 04/07/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111799
Principal investigator 1 Alnylam Pharmaceuticals Inc. $330.00 04/07/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111853
Principal investigator 1 GlaxoSmithKline, LLC. $384.90 04/03/2023 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 1006195561
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109023
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109029
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109035
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109041
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109047
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109051
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109059
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109065
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109071
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109077
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109083
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109089
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109095
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109101
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109107
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109113
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109119
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109127
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109133
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109139
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109143
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109151
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109157
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109163
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109169
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997109175
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109181
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109187
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109193
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109199
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109205
Principal investigator 1 Alnylam Pharmaceuticals Inc. $9,465.30 03/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111001
Principal investigator 1 Alnylam Pharmaceuticals Inc. $48,636.90 03/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111063
Principal investigator 1 Alnylam Pharmaceuticals Inc. $16,921.80 03/17/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110995
Principal investigator 1 Alnylam Pharmaceuticals Inc. $45,163.80 03/15/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111057
Principal investigator 1 Alnylam Pharmaceuticals Inc. $195.00 03/08/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110893
Principal investigator 1 Alnylam Pharmaceuticals Inc. $680.00 03/08/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110897
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,500.00 03/08/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110935
Principal investigator 1 Alnylam Pharmaceuticals Inc. $434.00 03/08/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111031
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,526.00 03/08/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111037
Principal investigator 1 Alnylam Pharmaceuticals Inc. $93.00 03/08/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111045
Principal investigator 1 Alnylam Pharmaceuticals Inc. $476.00 03/08/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111051
Principal investigator 1 Alnylam Pharmaceuticals Inc. $392.00 03/08/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111087
Principal investigator 1 Alnylam Pharmaceuticals Inc. $299.00 03/08/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111105
Principal investigator 1 GlaxoSmithKline, LLC. $751.21 03/03/2023 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 1006195605
Principal investigator 1 Alnylam Pharmaceuticals Inc. $128,863.80 03/01/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110989
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108761
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108767
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108773
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108779
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108785
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108791
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108797
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108803
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108809
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108815
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108821
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108827
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108833
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108839
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108845
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108851
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108859
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108865
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108871
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108877
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108881
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108889
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108895
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108901
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108907
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108913
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108919
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108925
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108931
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108937
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108943
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108949
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108955
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108961
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108967
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108973
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108979
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108987
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109005
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109011
Principal investigator 1 Alnylam Pharmaceuticals Inc. $523.60 02/28/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997109015
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,145.00 02/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110861
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,516.00 02/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110867
Principal investigator 1 Alnylam Pharmaceuticals Inc. $780.00 02/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110887
Principal investigator 1 Alnylam Pharmaceuticals Inc. $192.00 02/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110915
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,500.00 02/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110923
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,107.00 02/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110929
Principal investigator 1 Alnylam Pharmaceuticals Inc. $122.00 02/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110971
Principal investigator 1 Alnylam Pharmaceuticals Inc. $204.00 02/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110977
Principal investigator 1 Alnylam Pharmaceuticals Inc. $505.00 02/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110983
Principal investigator 1 Alnylam Pharmaceuticals Inc. $110.00 02/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111075
Principal investigator 1 Alnylam Pharmaceuticals Inc. $198.00 02/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111099
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,516.00 02/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111111
Principal investigator 1 Alnylam Pharmaceuticals Inc. $204.00 02/22/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111123
Principal investigator 1 GlaxoSmithKline, LLC. $3,226.74 02/22/2023 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 1006195551
Principal investigator 1 Alnylam Pharmaceuticals Inc. $212.80 02/15/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108993
Principal investigator 1 Alnylam Pharmaceuticals Inc. $67.20 02/15/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108999
Principal investigator 1 Janssen Research & Development, LLC $5,580.00 02/15/2023 Non-covered Recipient Entity
Pharmax Rsrch Clnc
67953964MDD3003 No dispute reported 06/30/2026 986108735
Principal investigator 1 GlaxoSmithKline, LLC. $375.60 02/01/2023 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 1006195615
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108569
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108576
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108583
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108588
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108595
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108601
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108607
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108613
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108619
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108625
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108631
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108637
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108643
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108651
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108657
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108663
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108669
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108675
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108681
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108687
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108693
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108697
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108703
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108709
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997108716
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108723
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108729
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108737
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108743
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108749
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997108755
Recipient Eli Lilly and Company $250.00 01/31/2023 Covered Recipient Physician A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) No dispute reported 06/30/2026 1038054357
Principal investigator 1 Alnylam Pharmaceuticals Inc. $8,100.00 01/25/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110965
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,120.00 01/23/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110849
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,584.00 01/23/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110855
Principal investigator 1 Alnylam Pharmaceuticals Inc. $256.00 01/23/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110903
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,476.00 01/23/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110909
Principal investigator 1 Alnylam Pharmaceuticals Inc. $244.00 01/23/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110953
Principal investigator 1 Alnylam Pharmaceuticals Inc. $272.00 01/23/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110959
Principal investigator 1 Alnylam Pharmaceuticals Inc. $220.00 01/23/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111069
Principal investigator 1 Alnylam Pharmaceuticals Inc. $264.00 01/23/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111093
Principal investigator 1 Alnylam Pharmaceuticals Inc. $272.00 01/23/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997111117
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,170.00 01/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110873
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,904.00 01/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997110879
Principal investigator 1 Alnylam Pharmaceuticals Inc. $124.00 01/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111013
Principal investigator 1 Alnylam Pharmaceuticals Inc. $234.00 01/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111019
Principal investigator 1 Alnylam Pharmaceuticals Inc. $136.00 01/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111025
Principal investigator 1 Alnylam Pharmaceuticals Inc. $112.00 01/20/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111081
Principal investigator 1 Alnylam Pharmaceuticals Inc. $9,780.30 01/13/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110947
Principal investigator 1 ABBVIE INC. $525.60 01/12/2023 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 998365985
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,925.00 01/09/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110835
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,400.00 01/09/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110843
Principal investigator 1 Alnylam Pharmaceuticals Inc. $33,881.40 01/06/2023 Non-covered Recipient Entity
Pharmax Research Clinic
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 997111007
Principal investigator 1 GlaxoSmithKline, LLC. $375.60 01/06/2023 Non-covered Recipient Entity
PHARMAX RESEARCH CLINIC INC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 1006195593
Principal investigator 1 Alnylam Pharmaceuticals Inc. $7,524.00 01/04/2023 Non-covered Recipient Entity
Pharmax Research Clinic
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 997110941